Harrasser, Micaela
Gohil, Satyen Harish
Lau, Hiu
Della Peruta, Marco
Muczynski, Vincent
Patel, Dominic
Miranda, Elena
Grigoriadis, Kristiana
Grigoriadis, Anita
Granger, David
Evans, Rachel
Nathwani, Amit Chunilal
Funding for this research was provided by:
National Institute for Health Research (NIHR) Blood and Transplant Research Unit
NHS Blood and Transplant
Wellcome Trust
Kay Kendall Leukaemia Fund
Article History
Received: 22 June 2020
Accepted: 17 May 2022
First Online: 3 June 2022
Declarations
:
: All animal studies were performed under the authority of the United Kingdom Home Office Project and Personal License regulations and were compliant with University College London guidelines.
: Not applicable.
: SHG, MDP and ACN hold patent rights for ROR1‐based immunotherapies. ACN and VM are employees of Novalgen Limited, and ACN and VM hold equity in Novalgen, which has licensed ROR1-based immunotherapies from University College London.